Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

Cancer chemotherapy and pharmacology - 1 Jan 2010

Thiessen Brian, Stewart Clinton, Tsao Ming, Kamel-Reid Suzanne, Schaiquevich Paula, Mason Warren, Easaw Jacob, Belanger Karl, Forsyth Peter, McIntosh Lynn, Eisenhauer Elizabeth

Abstract excerpt

PURPOSE: We undertook a phase I/II study of the EGFR/erbB2 inhibitor lapatinib in patients with recurrent glioblastoma multiforme (GBM) to determine response rate, pharmacokinetics (PK) and recommended dose in patients taking enzyme-inducing anti-epileptic drugs (EIAEDs) and to explore relationships of molecular genetics to outcome. METHODS: Recurrent GBM patients taking EIAEDs were enrolled on the phase I...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to Cytochrome P-450 CYP3A

Share to Enzyme Induction

Share to Lapatinib

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 19499221
DOI: 10.1007/s00280-009-1041-6

Genes

PTEN
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.PMID 19499221Read ↗

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.Semantic proximity Read ↗

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.Semantic proximity Read ↗

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.Semantic proximity Read ↗

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.Semantic proximity Read ↗

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.Semantic proximity Read ↗

Targeting EGFR in glioblastoma with a novel brain-penetrant small molecule EGFR-TKISemantic proximity Read ↗

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.Semantic proximity Read ↗

A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.Semantic proximity Read ↗

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.Semantic proximity Read ↗

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.